Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender Sells 12,048 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 12,048 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Day One Biopharmaceuticals Trading Up 1.6 %

Day One Biopharmaceuticals stock opened at $12.43 on Friday. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46. The company’s 50-day moving average price is $12.37 and its two-hundred day moving average price is $13.47. Day One Biopharmaceuticals, Inc. has a 52 week low of $11.13 and a 52 week high of $18.07.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $27,000. R Squared Ltd bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares in the last quarter. Quest Partners LLC boosted its position in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after purchasing an additional 9,603 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on DAWN shares. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. The Goldman Sachs Group dropped their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, February 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.